sábado, 14 de noviembre de 2026
BuscarExplore
Via News Knowledge File

Newmont Corporation

organization80% conf.·synced Aug 13, 2026

Previous owner of CC&V mine, retains 90% closure cost liability if exceeds $500M

53
sourced metrics
198
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Share
9.2percent
Jul 21, 2026source
Jv Ownership Percentage
61percent
Jul 14, 2026source
New Buyback Program
6.0USD
Jun 27, 2026source
Buybacks Executed
6.0USD
Jun 27, 2026source
Gold Production Oz Guidance
5260000oz
Jun 27, 2026source
Buybacks Since Q4 2025 Earnings
2.4USD
Jun 27, 2026source
Shareholder Distributions
2.7USD
Jun 27, 2026source
Payout Ratio
12percent
Jun 27, 2026source
Margin
12percent
May 14, 2026source
Cash
3.1USD
May 1, 2026source
Gold Production
1.3million_oz
Apr 29, 2026source
Buyback Authorization New
6USD
Apr 29, 2026source
Cumulative Divestiture Proceeds
4.6USD
Apr 29, 2026source
Sustaining Capital Expenditure
381USD
Apr 29, 2026source
Eps
2.90USD
Apr 29, 2026source
Gold Aisc Byproduct
1029USD_per_oz
Apr 29, 2026source
Ghana Royalty Cost Headwind
25USD_per_oz
Apr 29, 2026source
Share Buybacks Since Last Call
2.4USD
Apr 29, 2026source

Stated objectives

Produce 5.6 million ounces of gold in 2025

source
target: 5.6 million ounces by 2025-01-01 00:00:00stated

2026 gold production forecast

source
target: 5.3 million ounces by 2026-12-31 00:00:00stated

Maintain gold production at approximately 5.9 million ounces for 2025

source
target: 5.9 million ounces by 2025-01-01 00:00:00stated

Fourth quarter production of 1.415 million ounces

source
target: 1.415 million ounces stated

Generate $3 billion in after-tax cash proceeds from 2025 divestiture program

source
target: $3 billion by 2025-01-01 00:00:00stated

Ahafo North to produce 50,000 ounces in first year with ramp-up to full capacity (275,000-325,000 ounces annually) in 2026

source
target: 50,000 ounces (2025), 275,000-325,000 ounces (2026+) by 2026-01-01 00:00:00stated

Continue deleveraging and maintain near-zero net debt position

source
target: near-zero net debt stated

Achieve approximately 6 million ounces of gold production annually

source
target: 6 million ounces by 2027-01-01 00:00:00stated

Achieve 150,000 tonnes of copper production annually

source
target: 150000 tonnes by 2027-01-01 00:00:00stated

Produce 5.3 million ounces of gold in 2026

source
target: 5.3 million ounces by 2026-12-31 00:00:00stated

Relationship graph · 198 connections

Owns
46
Competes with
33
Covered by
26
owned by
14
Invested in
11
Employs
10
located in
9
regulates
8
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com